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KESAN MINYAK KELAPA DARA KE ATAS INFLAMASI SALUR 
PERNAFASAN DAN SEL REMBESAN MUKUS DI DALAM MODEL 
HAIWAN KECEDERAAN PARU-PARU KRONIK 
ABSTRAK 
Peningkatan kadar kekerapan penyakit asma telah menjadikan penyakit ini tersenarai 
sebagai nombor tiga di antara penyakit berisiko tinggi di seluruh dunia. Sedutan 
terapi dadah yang sering di beri pada masa kini bagaimanapun telah dilaporkan 
dengan kesan sampingan yang teruk, terutama pada fungsi paru-paru dengan 
penggunaan jangka masa panjang. Dalam kajian ini, minyak kelapa dara telah 
diberikan kepada model haiwan asma untuk membuat pemerhation terhadap kesan 
sedutan minyak kelapa dara pada penyusupan sel inflamatori salur pernafasan, 
pembentukan semula struktur saluran udara (ketebalan epitelium, mukosa dan 
submucosa), hiperplasia sel goblet dan aktiviti proliferasi sel epitelium setelah 
didedahkan kepada alergen. Arnab telah disensitifkan dengan suntikan gabungan 
ovalbumin dan alum dan diikuti dengan sedutan ovalbumin. Ini bertujuan untuk 
mencetuskan serangan asma. Model asma kemudiannya diberikan rawatan dengan 
minyak kelapa dara secara sedutan melalui laluan menyelamat (minyak kelapa dara 
sebagai kumpulan ejen penyelamat) dan laluan pencegahan (VCO sebagai kumpulan 
ejen pencegahan). Analisis GC -MS untuk mengenalpasti sebatian yang mempunyai 
kebolehan sebagai anti-radang dan anti-asma juga telah dijalankan. Keputusan 
menunjukkan pengurangan ketara dalam kumpulan menyelamat dari segi infiltrasi 
sel radang, ketebalan struktur saluran udara (epitelium dan mukosa) dan bilangan sel 
goblet. Pengurangan juga diperhatikan pada aktiviti proliferasi sel epitelium saluran 
udara. Dalam kajian ini, analisis GC-MS telah menunjukkan bahawa terdapat dua 
xvii 
 
komponen yang mungkin menyumbang kepada keberkesanan rawatan minyak kelapa 
dara secara sedutan, iaitu asid laurik (40.86 %) dan asid capric (5.17 %). Secara 
kesimpulan, kajian ini menunjukkan bahawa kedua-dua kumpulan rawatan minyak 
kelapa dara mempunyai potensi sebagai ubat anti-asma. Walau bagaimanapun, 
pemerhatian yang lebih baik dapat ditunjukkan dalam kumpulan penyelamat, dan ini 
dapat disimpulkan bahawa minyak kelapa dara adalah lebih sesuai untuk bertindak 
sebagai ubat bagi melegakan atau mengurangkan serangan asma, tetapi tidak boleh 
mencegah tercetusnya asma semasa pemekaan alergen pada saluran udara. Walau 
bagaimanapun, kajian mendalam pada masa hadapan perlu dilakukan untuk 
menentukan laluan di mana minyak kelapa dara mampu mengurangkan tindak balas 
sel dalam alahan asma, 
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THE EFFECT OF VIRGIN COCONUT OIL (VCO) ON AIRWAY 
INFLAMMATION AND MUCUS SECRETING CELLS IN AN ANIMAL 
MODEL OF CHRONIC LUNG INJURY 
ABSTRACT 
A high prevalence of asthma over the years make the disease become a number three 
among list of live-risked disease worldwide. Inhalation of current drug therapies 
however has been recorded with severe side effects on the lung function, due to long 
term usage. In this study, virgin coconut oil (VCO) was given to animal model of 
asthma as to observe the effect of the inhalation of VCO on the infiltration of airway 
inflammatory cell, remodelling of airway structures (epithelium, mucosa and 
submucosa thickness), goblet cell hyperplasia and the proliferation activity of airway 
epithelial cells following the allergen exposure. The rabbits were elicited with 
combination of ovalbumin and alum injection and followed with ovalbumin 
inhalation, in order to induce the onset of asthma. The asthma model was then given 
the treatment with VCO-inhalation via rescue route (VCO as rescue agent group) and 
preventive route (VCO as preventive agent group). The GC-MS analyses for possible 
anti-inflammatory and anti-asthmatic compounds were also carried out. Result 
showed a significant reduction in the rescue group in terms of infiltration of 
inflammatory cell, thickness of airway structure (epithelium and mucosa) and goblet 
cell numbers. Reduction was also observed on the proliferation activity of the airway 
epithelial cell. In this study, the GC-MS analyses showed there were two possible 
components that might contribute to the effectiveness of VCO-inhalation, which was 
lauric acid (40.86%) and capric acid (5.17%). As a conclusion, the study showed that 
both treatment groups exhibited promising result for the VCO as anti-asthmatic 
xix 
 
remedies. However, better outcome was observed in rescue group, which can be 
concluded that the VCO was more suitable to act as medication in relieving or 
reducing the asthma attacks, but not to prevent the asthma onset during allergen 
sensitization in the airway. However, extensive future study needs to be carried out 
in order to determine the pathway in which the VCO was able to reduce the cellular 
response of allergic asthma. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Research Overview 
Asthma is an airway disorder that is characterised by a specific pattern of 
inflammation that is largely driven via immunoglobulin (Ig) E-dependent 
mechanisms in the airway (Barnes, 2008). The pathophysiology of asthma is 
complex and involves airway inflammation, intermittent airflow obstruction and 
bronchial hyperresponsiveness. During the attacks, swelling of the airway smooth 
muscle or smooth muscle hypertrophy limits the airflow, thus reduces the amount of 
air that can pass by (Barnes, 2008, Bentley and Hershenson, 2008). In asthma 
patients, common signs and symptoms develop during asthma attack are chest 
tightness, coughing, wheezing and difficulty in breathing. Asthma onset can be 
triggered by internal and external factors, which are environmental allergens, animal 
hair, dust, viral respiratory tract infections, exercise, irritants, emotional factors or 
stress, cigarette smoke and changes in weather (Keir and Page, 2008, Hernandez et 
al., 2012). 
According to asthma association in United Kingdom (UK), asthma is extremely 
common and affects people regardless of ages and social background. In the UK, one 
in every five (1/5) household is exposed to asthma onset in their lifetime. It is 
estimated that 5.4 million of UK population are currently treated for asthma, which 
4.3 million is adults and the remaining is children with known diagnosis of asthma 
(Asthma Association of UK). Three hundred million people worldwide also have 
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been estimated to have asthma with one for every 250 death. According to National 
Medicines Use Survey (NMUS) of Malaysia in 2006, asthma was ranked the 3rd 
highest amongst chronic disease as reported in the Third National Health and 
Morbidity Survey (NHMS III). In clinical treatment for asthma, glucocorticoid is the 
most used drug for relieving asthma symptoms in patients. However, according to 
Weiner et al. (1992), long term treatment with glucocorticoids in higher doses may 
cause inspiratory muscle weakness (Weiner et al., 1992).  
Recently, the trends of using natural-based products as an alternative and 
complementary medicine for treatment of critical diseases like cancer are growing 
over time. There are many researches that using plant-based materials to block the 
possible route to disease onset (Popova et al., 2005, Gao et al., 2011, Althunibat et 
al., 2013). Anti-asthmatic and anti-inflammatory effect of several plant-based 
therapies has been done by several researchers, where they look into the effect of 
thymoquinone (TQ) from Nigella sativa’s seed, curcumin from Curcuma longa L, 
marine red alga (Laurencia undulate), Bambusae Caulis in Taenim extract and 
Lagerstroemia indica on animal model of chronic and acute airway inflammation (El 
Gazzar et al., 2006, Jung et al., 2009, Ra et al., 2010, Yang et al., 2011, Karaman et 
al., 2012). A study by Yang et.al (2008) which used Duchesnea chrysantha (Dc) to 
examine the effect of extract on leukocyte infiltration and mucus secretion reported 
that the Dc extract reduced the inflammation due to leukocyte infiltration and mucus 
hyperproduction by goblet cells (Yang et al., 2008).  Other than that, anti-
inflammatory activities of Cinnamomum cassia (Cc) in LPS-model of mouse has 
been conducted by a team from Taiwan (Liao et al., 2012), where they found out that 
cinnamic aldehyde (Cs constituent) was able to increase the activities of antioxidant 
enzymes.  
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1.2 Lung Disease 
Lung disease or also known as respiratory disease is the commonest medical 
condition worldwide, as reported in United States, Canada and also Malaysia. The 
contribution to the high medical record, statistics can be due to the smoking habits, 
infections as well as the genetics factors (Siddiqui and Brightling, 2007, Vercelli, 
2008, Weiss et al., 2011, Lau et al., 2012). Normal and healthy lung conditions 
provides sufficient forces in inhaling oxygen and expelling carbon dioxide into and 
out from the lung. However, abnormalities in lung function which involve changes 
on the normal structures of the airway tree resulting in difficulties in breathing and 
other life-threatening cases such as asthma, chronic obstructive pulmonary disease 
(COPD), infectious lung diseases, lung cancer, tuberculosis and cystic fibrosis.  
1.3 Chronic Lung Disease 
Chronic lung disease or chronic respiratory diseases are commonly used terms to 
refer to chronic lung diseases such as COPD, asthma, chronic bronchitis and 
emphysema (Jeffery, 2001, Goldklang et al., 2013). These diseases are worsening 
over time and cause difficulties in patients living with the circumstances. Under such 
conditions, chronic lung disease can cause narrowing of the airways lumens (Figure 
1.1) which in turn limiting the volume of air in and out from lungs and causes 
shortness in breathing. Patients living with chronic lung disease often coughing, 
produce more mucus and having shortness in breath. These symptoms will develop 
after several years living with unhealthy environment and lifestyle, such as smoking 
and air pollution, especially in industrial areas (Van Lieshout and MacQueen, 2008). 
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Figure 1.1 Normal airway (A) vs asthmatic airway (B). Airway in normal 
condition permits sufficient exchange of air during inhalation and exhalation proses 
(A). The airways of chronic lung disease (asthmatic airway) (B) are inflamed due to 
the epithelium hyperplasia, goblet cell hyperplasia, smooth muscle hypertrophy 
which in turn blocks the airway passage, causing difficulties and shortness in 
breathing (Adapted and modified from Fahy, Corry, & Boushey, 2000). Keyword: C-
cartilage. 
 
1.3.1 Asthma  
Asthma is a chronic inflammatory disorder of the airways which involves numbers of 
inflammatory cells such as mast cells, eosinophil and T lymphocytes. From a 
pathologic standpoint, asthma is characterized by a combination of hyperplasia and 
hypertrophy of the smooth muscle bundle in both small and large airways (Woodruff 
et al., 2004, Zhang et al., 2004). In asthma patients, the inflammation action of the 
cells may cause repeated wheezing, breathless, chest tightness and cough. The 
symptoms particularly take place at night and/or in the early morning. The changes 
in temperature of the air serve as external stimulus in asthma. Smoking, one of the 
common lifestyle nowadays, also can contribute to asthma onset as being reported in 
a research by Goldklang et.al (2013).  
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Cigarette smoke, home mite and dust is the commonly external stimuli that can 
activate series of action of gene expression that later induces asthma onset (Townley 
and Horiba, 2003, Schraufnagel et al., 2010). The stimuli detected by receptor on 
cells will activate the action of Th2 lymphocytes which will produce inflammatory 
cytokines. Inflammatory cytokines involve in asthma is interleukin (IL) 4, 5, 9 and 
13. The actions of these cytokines will inflame the airway muscle thus remodel the 
airway structure and cause blockage of respiratory process (Zhen et al., 2007, Krane 
et al., 2009). The airway lumen is blocked by mucus overproduction by goblet cells 
that consist of plasma protein from airway vessels and mucus glycoprotein by goblet 
cells hyperplasia (Hallstrand et al., 2012).  
In airway remodelling, there are several changes occurs during the process. The 
changes involved epithelial goblet cell hyperplasia and metaplasia, collagen 
deposition and thickening of the lamina reticularis, smooth muscle hyperplasia, and 
proliferation of airway blood vessels (Davies et al., 2003). Hyperplasia is the process 
of increasing the goblet cells numbers while metaplasia is the ability of Clara cells 
and nonciliated cells to transform into goblet cells after sensitization occur (Curran 
and Cohn, 2010). 
1.4 Cellular Arrangement of the Lungs 
Lung consists of several cell types that line up the inner layer of the airway cavity. 
During the process of lung morphogenesis and after acute and chronic lung injury, 
the cells that build up the lungs differs due to the numbers, localization, and function 
of each cell niches vary dynamically (Cardoso and Whitsett, 2008)  Airway epithelial 
cells of the lungs, such as alveolar type I (AT I), alveolar type II (AT II), nonciliated 
cell (clara cell), basal cell, goblet cells and also ciliated cells were differentiate and 
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interact with each other in maintaining the cellular composition of the respiratory 
system (Park et al., 2006, Cardoso and Whitsett, 2008, Franks et al., 2008). In mature 
lung, the lung surface is equipped with the nonproliferative, slow rates of mitosis, 
and prolonged survival of the resident cells (Cardoso and Whitsett, 2008). Most of 
the cells that can be found in normal lung are alveolar type I, alveolar type II and 
also clara cell, and these cells serve as the progenitor cells of the airway epithelial 
and actively involved in repair process during the lung injury (Kotton and Fine, 
2008, Liu and Engelhardt, 2008, Rawlins, 2008). After infection, inflammation or 
exposure to toxic substances, the proliferation and differentiation capability of the 
progenitor cell will be activated. Alveolar type I which cover about 95 percent of the 
alveolar surface area is the squamous epithelial cells which responsible in forming 
the alveolar wall and will be degenerated during injury (Dobbs et al., 1998, McElroy 
and Kasper, 2004, Wong and Johnson, 2013). Unfavourable condition to the airway 
exchange process will turn on the repair pathway in alveolar type II. Alveolar type II, 
which is the progenitor cell to alveolar type I will be proliferated and differentiate 
rapidly into alveolar type I cells, thus replacing the injured cells (Figure 1.2). 
Alveolar type II (ATII) cells are cuboidal cells that made up the remaining 5 percent 
of the alveolar wall (Wu and Wei, 2004, Akram et al., 2013). Alveolar type II cells 
function in secreting the surface surfactant, control fluid levels and replace injured 
cells during exposure to the toxicant substances (Zheng et al., 2013). Other than 
alveolar type II, nonciliated columnar and basal cells can proliferate into other 
respiratory cells, such as Clara cells, goblet cells and also ciliated cells. Goblet cells 
are mainly involved in the mucus hyperproduction during asthmatic attacks (Ordonez 
et al., 2001). The increasing in the mucus production is related to the contribution of 
the infiltration of the inflammatory cells into the airway cavity. Goblet cell 
7 
 
metaplasia, which evolved from the nonciliated and maybe ciliated cells, is 
associated with the loss of the Foxa2 genes (Cardoso and Whitsett, 2008). 
Figure 1.2 The involvement of alveolar cells during injury. Exposure to allergen 
causes injury will turn on the repair pathway in alveolar type II (ATII). The 
unfavourable condition activates the proliferation and differentiation capability of 
alveolar type II (ATII) cells which rapidly turn into alveolar type I cells, replacing 
the injured cells.  (Adapted and modified from 
http://tigger.uic.edu/depts/mcph/lab_yuru.htm) 
1.5 Rabbit as Animal Model of Chronic Lung Injury 
Remodelling acute lung injury in medical research prospect is important in finding 
and understanding of the mechanism relying behind acute and chronic disease. In 
drug discovery study, animal has been used in eliminating the needs on manipulating 
human in research. The development of therapeutic strategies against complex 
disease requires animal as a model to mimic the aspects of respiratory diseases (Van 
der Velden and Snibson, 2011). In remodelling of human respiratory system, the 
reason in using the animal as method of the study is that the animals provide 
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experimental settings that allow us to understand the interaction between immune 
system with a functioning respiratory system.  
In the requirement for choosing suitable animal to be used in the research, there are 
several aspects that need to be taken into consideration i.e. the ability of the animal to 
reproduce the principle aspects of the human lung disease, size of the animal, the 
accessibility to the research reagents, as well as cost in handling the animal. In order 
to mimic the pathophysiology of a human lung disease, animal with large size is the 
most suitable to be used since the complexity of the organ structure is more similar 
and identical to human as compared with small size animals (Matute-Bello et al., 
2008). In developing the animal model of chronic lung injury, rabbit is a suitable 
candidate, due to its ability to develop disease from the point being sensitized with 
allergen for a prolonged period (Matute-Bello et al., 2008). 
In a report by Keir and Page (2008), where the study used rabbit as a model for 
asthma and other lung diseases indicated that the allergic rabbit is sensitive to similar 
drugs as patients with asthma (Keir and Page, 2008). One of the drugs for asthma 
patients that can be used in airway disease is corticosteroid. The administration of 
budesonide; one type of corticosteroid in rabbit sensitized by inhalation exhibiting a 
marked anti-inflammatory activity, inhibits antigen-induced airway 
hyperresponsiveness and bronchodilator responses (Gozzard et al., 1996). 
Budesonide also can inhibit the early and late response of the airway 
hyperresponsiveness, as well as eosinophil infiltration (Keir and Page, 2008).  
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1.6 Activation of the Proliferating Genes during Repair Process 
Imbalance of the cells niche after injury process will trigger the activation of several 
genes that regulating the maintaining of the cellular compositions. Proliferating cell 
nuclear antigen (PCNA) is one of the genes that actively involved during resting, 
proliferation, differentiation and programmed cell death (apoptosis) (Kubben et al., 
1994, Kelman, 1997, Paunesku et al., 2001). PCNA is highly expressed in the 
cycling cells and occur during the last 5% of G1-phase and the first 35% of S-phase 
(Kubben et al., 1994, Paunesku et al., 2001, Essers et al., 2005). The action of PCNA 
in cells is closely regulated by the p53 and p21 genes, which genes involving in the 
cell death decision either entering cell cycle arrest and undergo DNA repair or 
apoptosis when repair is impossible (Paunesku et al., 2001). When PCNA is driven 
by the p53 genes, PCNA commits the cells to cell cycle arrest and repair the DNA 
damage. Otherwise, when the repair is impossible, the level of functional PCNA is 
reduced and drives the cells into apoptosis stage (Paunesku et al., 2001). Other than 
that, a study by Koundrioukoff et al. (2000) showed that there was direct interaction 
between PCNA and CDK-2 (cyclin-dependent kinase 2), forming PCNA-Cdk2-
cyclin A complex.  
1.7 Established treatment for lung diseases  
The lung serves as the second largest organs in the body and the development of lung 
cancer can reduce the efficacy and function of the human respiratory system in 
protecting the body. In preventing and treating lung diseases, some patients are 
subjected to undergo treatment session where they will be exposed to the various 
series of drugs that can combat and reduce the progression of the disease. However, 
there is a possibility in developing drug resistance in a cancer lineage which can be 
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due to the genetic changes in the normal cells where may induce changes in their 
biochemical properties and chemosensitivity (Nishio et al., 1999).  
In treating and reducing the pain of asthma attacks, common drugs being prescript to 
the patients are salbuterol or salbutamol, short-acting beta agonists (SABA) inhaled 
bronchodilators that rapidly ease asthma symptoms (Pickholtz et al., 2011); 
omalizumab, given as injection which help by altering the immune system (Perkins 
et al., 2007); and also salmeterol, a long-acting beta agonist (LABA) that can open 
the airways by effectively aid in bronchodilatation for at least 12 to 18 hours 
(Spector, 1991). However, in using these kinds of drugs to treat the asthma attacks, 
there are possibilities in worsening the attacks instead of reducing it. As for SABA 
treatment, it can induce allergic reaction, difficulty in breathing, swelling of the 
mouth and for LABA, the side effects are quite similar to the SABA treatment but 
with increasing possibility in asthma exacerbations and risk of fatal asthma cases.  
Despite the side effects of chemotherapy for cancer and drugs treatment for asthma 
attacks, there is a need in exploring new natural-based remedies which can be apply 
in treating the acute and chronic diseases. Several natural products serve as 
anticancer for lung cancer has been passing the clinical trial stages, such as 
Catharanthus roseus (Lu et al., 2003, Nirmala et al., 2011), Campthotheca 
acuminate (Lisa et al., 2001, Nirmala et al., 2011) , Berberineeris sp. (Han et al., 
2010, Nirmala et al., 2011), Tabeuia avellanedae (Nirmala et al., 2011, Higa et al., 
2011) , Vicia faba, Amoora rohituka (Mans et al., 2000) and Dysoxylum  
binectarierum (Nirmala et al., 2011) . In treating asthma, such natural products that 
has been claimed to be effective against the asthma attacks are ginkgo biloba 
(Babayigit et al., 2009), traditional Chinese medicine; Mai Men Dong Tang, Ding 
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Chuan Tang and also STA-1 (Kopnina, 2012), reishi mushroom (Halpern, 2007), 
curcumin (Kurup and Barrios, 2008).  
1.7.1 Virgin coconut oil (VCO) as potential anti-inflammatory and anti-
asthmatic agent 
Coconut (Cocos nucifera L.) is commonly growth at tropical country, especially in 
Asia region. A coconut consists of husk, hard shell, copra and water, which 
dominantly occupied the fruit. A mature coconut often harvested and served as raw 
materials; copra for coconut oil production, hard shell to be used in charcoal 
industries and husk can be used to make coir (Figure 1.3). Commonly used part in 
the coconut is the endoderm or copra. Copra, with high oil content with about 65-
75% oil (DebMandal and Mandal, 2011) is usually used in both food and non-food 
industries, such as soap, lotion or margarine production. The mass production of the 
by-product requires large scale of the coconut oil supply and Malaysia produce about 
52.17% of coconut oil in 2013 to fulfil the requirement for the industries (United 
States Department of Agriculture). Coconut oil can be extracted from the copra meat 
through various methods, such as traditional heat-expelling method and solvent 
extraction method (Nevin and Rajamohan, 2009). Both methods extremely affect the 
nutritional content of the coconut oil due to the heat applied during processing 
methods. Moreover, the coconut oil or also known as Refined, Bleached and 
Deodorized (RBD) oil turn out to be not as beneficial as virgin coconut oil (VCO) 
since the coconut fat is deodorized at a maximum temperature of 220°C for 4 hours 
at a pressure between 3-5 bar and need to be purified prior human consumption due 
to the unsanitary drying processing of the copra.  
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Figure 1.3 Cross-section of a coconut (Coconut nucifera L.). The mature coconut 
often harvested to be used in industries production of coir (husk), charcoal (hard 
shell), and coconut oil (copra).   
 
Currently, the trend in consuming natural products has been greatly impact the 
growth of interest on VCO. VCO is widely used around the world, especially in 
tropical region such as South and Central America, Africa, Indian subcontinent and 
commonly used in Asia, especially in Malaysia, Thailand and Philippines (Verallo-
Rowell et al., 2008, Marina et al., 2009). In contrast with RBD coconut oil, the VCO 
is obtained directly from coconut milk by wet process under controlled temperature, 
which can prevent the loss of biologically active minor components like vitamins and 
polyphenols (Zakaria et al., 2011a, Zakaria et al., 2011b). VCO is one of the natural 
products that rich in antioxidants which high in phenolic acid (ferulic acid, and p-
coumaric acid) (Liau et al., 2011, Marina et al., 2009, Nevin and Rajamohan, 2009, 
Zakaria et al., 2011a). According to APCC (Asian and Pacific Coconut Community) 
standard for VCO, most detectable free fatty acids is lauric acid (C12:0), with 45-
56% of total content, followed by ranges of fatty acids with 6-18 carbon chains.  
Free fatty acids available in this natural oil has been studied their beneficial effects 
on many aspects of health diseases. Various studies has been done by scientists 
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worldwide with some reported that VCO exhibits anti-bacteria (Nevin and 
Rajamohan, 2010), anti-viruses, anti-HIV, anti-inflammatory properties (Zakaria et 
al., 2011b), anti-diabetes (Nevin and Rajamohan, 2004, Liau et al., 2011), and has 
been extensively used as topical application in treating skin disorders (Agero and 
Verallo-Rowell, 2004, Verallo-Rowell et al., 2008, Nevin and Rajamohan, 2009). 
Study by Badlishah S et.al (2013) showed that VCO able to prevent blood pressure 
elevation and improves endothelial function in rats (Nurul-Iman et al., 2013). The 
efficacy and safety of the virgin coconut oil in reducing visceral adiposity also has 
proved that the VCO is efficacious as weight reducing and safe for human 
consumption (Liau et al., 2011).  A study on toxicity of the VCO has been done by a 
group of researchers from USM. The study tested the VCO on rat model of acute 
toxicity test, where they found that high dosage (2000mg/kg) of oral consumption of 
VCO give no visible signs of toxicity and mortality (Ahamed et al., 2011). The 
available study on treating cancer using VCO has been done by Calderon et.al (2009) 
and Law et al. (2014) where they investigated the effect of VCO on breast cancer 
progression both in vitro and in vivo (Law et al., 2014, Calderon et al., 2009). 
However, to date, such study in assessing the effectiveness of VCO in alleviating 
asthmatic cellular response has never been reported by other researchers. In order to 
fill in the gap between traditional claim and scientific-based evident, this study was 
aimed to evaluate the efficacy of the VCO either reducing the asthma pathogenesis or 
preventing the onset of asthma. 
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1.8 Objectives of the study 
1.8.1 General objective 
The main objective of this study was to investigate the effects of aerosolisation of 
VCO on ovalbumin-induced (Ova) airway injury, which involved the inflammatory 
cell infiltration, airway remodelling and mucus overproduction. 
1.8.2 Specific objectives 
 
 The specific objectives of this study;  
a) To investigate the effect of VCO treatment on the pathophysiological changes 
of the airway structures (epithelium, mucosa and submucosa) in response to 
Ova-induced airway injury. 
b) To investigate the effect of VCO treatment on inflammatory response 
(eosinophil, basophils, neutrophils, lymphocytes and monocyte) of the 
airways following Ova-induced airway injury.  
c) To study the effect of VCO treatment on mucus-producing goblet cells 
following Ova-induced airway injury. 
d) To study the effect of VCO treatment on the proliferation of the airway 
epithelial cells following Ova-induced airway injury.  
e) To screen the anti-inflammatory related active compounds of the crude 
extract of VCO using GC-MS profiling method.  
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1.9 Research Hypothesis 
 The inhalation of VCO using portable nebulizer is able to reduce the 
infiltration of inflammatory cells, which help in reconstructing the airway structure, 
reduce the goblet cell hyperplasia and the proliferation activity of the airway 
epithelial cells following injury in animal model of asthma. 
 1.10 Relevance of the Study 
This study was proposed to elucidate the effects of the VCO in alleviating the 
pathogenesis of asthma and/or preventing the onset of asthma-related cellular 
response. The availability of the commercialised drug-based products for asthma 
treatment have no doubt give significant effect on asthma pathogenesis, still with 
long list of side effects. The traditional use of VCO have been claimed to be effective 
in various diseases including asthma, but no scientific evident has yet available to 
demonstrate its efficacy in treating asthma. This study was aimed to provide 
scientific evidence in current therapy for asthma by using aerosol-based VCO 
treatment which can provide a better delivery route of the VCO into injured lungs 
compare to the common use of VCO (oral consumption and tropical application). 
This study was also aimed to provide an alternative way of treating asthma patients 
using aerosol-based VCO treatment, which mimicking drug delivery route of the 
current drug therapy for asthma (SABA or LABA) patient using portable nebulizer.  
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CHAPTER 2 
MATERIAL AND METHOD 
2.1 Overview of the study 
The study involved development of the animal model of chronic lung disease 
(asthma) by exposing to the i.p Ova and alum and Ova-inhalation. The animal were 
grouped into five different groups, which were naïve (untreated, normal animal), i.p. 
OVA (receive only i.p. Ova treatment), Ova-inhalation (receive i.p. Ova and 
inhalation of Ova), VCO as rescue agent (receive VCO as rescue treatment) and 
VCO as preventive agent (receive VCO as preventive treatment). After that, the 
samples (blood, BAL fluid and lung) were collected and proceed with sample 
analyses (Figure 2.1).  
 
Figure 2.1 The overview for the current study. The in vivo study was aimed to 
observe the effectiveness of VCO in reducing the injury level of ovalbumin-induced 
animal model.  
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2.2 The effect of VCO on the airway of rabbit model for asthma 
2.2.1 Source of VCO 
The VCO used in this study was purchased from Nutrifera Sdn. Bhd. (Kelantan 
Biotech Corporation, MY). 
2.2.2 Animal model  
Adult male New Zealand white rabbits (n=25), aged 4-6 months and weighted 2.60 ± 
0.38 kg, were used in this study. The ethical approval were obtained from The 
Animal Research Ethics Committee of USM (JEHUSM) (USM/Animal Ethics 
Approval/2012/ (77) (379) (Appendix 1). The rabbits were maintained in ventilated 
room and fed daily with water and pellets.  
The rabbits were divided into five independent groups (n=5 for each group) where 
two groups received allergen exposure and another two groups received VCO-
inhalation treatments and one serve as control (untreated).  Two groups that received 
allergen exposure were served as injury for; 1. intraperitoneal injection (i.p.) Ova 
only and 2. Ova-inhalation (i.p. Ova and Ova-inhalation). These two groups were 
combined together and later known as Ova-induced injury group, and another two 
served as treatment groups, which later known as the preventive and rescue groups. 
In Ova-induced injury group, the rabbits were sensitized with ovalbumin (i.p. Ova) 
twice, containing 1ml Ova (0.1 mg/ml ovalbumin, (Ova), grade V) (Sigma Aldrich, 
US) and 1 ml Alum (10 mg/ml aluminium hydroxide (alum)) (Thermo Fisher 
Scientific, US) on day 1 and 14 respectively (Figure 2.2). Twenty-four hours 
following second i.p. Ova injection, rabbits in i.p. Ova control group were 
euthanized. In Ova control group, the rabbits were aerosolized with 5 ml Ova (10 
mg/ml Ova) for three subsequent days (days 28, 29, and 30) using nebulizer 
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(MABISMist handheld Ultrasonic Nebulizer, US) for 20 mins and was euthanized on 
day 31.  
 
Figure 2.2 Intraperitoneal (i.p.) injection of ovalbumin on day 1 and 14 during 
asthmatic sensitization stage on the rabbits. 
 
As for the treatment groups, following the second i.p. Ova injection, the rabbits in 
both rescue and preventive groups were given repeated inhalation of 5 ml of 100% 
VCO (Nutrifera, MY) by using nebulizer for 20 mins for five days (± 2 ml/20 mins), 
which was from the day 23 until day 27. Following VCO-inhalation, the rabbits from 
rescue group were euthanized on day 28. However, in preventive group, following 
five days of VCO inhalation (day 23 until day 27), the rabbits were given 5 ml of 
Ova (10 mg/ml) inhalation for another three days, which was on day 28 until day 30. 
The rabbits were then euthanized on day 31st. Figure 2.3 represents the timepoint for 
each group that were subjected to the development of asthma and treated with the 
VCO. 
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Figure 2.3 Timeline for animal groups. Control group for Ova-inhalation; 
Control group for intraperitoneal injection of Ova (i.p. Ova); VCO as rescue agent; 
and VCO as preventive agent. Adapted and modified from (Kumar et al., 2008, 
Olmez et al., 2009, Lee et al., 2012, Kamaruzaman et al., 2014). 
 
2.2.3 Aerosolisation of VCO into the lung of the asthma-induced rabbits 
Ovalbumin-induced rabbits were treated via inhalation of VCO using nebulizer 
(Figure 2.4). The rabbits were given 5ml Ova (10mg/ml Ova in PBS) using the 
MabisMist™ Ultrasonic Nebulizer (MABIS Healthcare INC, US) for 20 mins. The 
MabisMistTM Ultrasonic Nebulizer is portable ultrasonic nebulizer that is commonly 
used for asthma treatment.  
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Figure 2.4 The aerosolisation process of VCO into the lungs of the rabbits using 
MabisMist™ Ultrasonic Nebulizer. The process takes 20 mins for a cycle to be 
completed.  
 
2.2.4 Blood collection for whole blood count (WBC) 
In this study, the blood was collected on day 28 or 31, prior to post-mortem of the 
rabbits. The rabbits were first anesthetised using ketamine (35 mg/kg) (Ilium, NSW, 
Australia) and ilium xylazyl (4 mg/kg) (Ilium, NSW, Australia) via intramuscular 
(i.m.) injection. Once the rabbits were unconscious, 5ml syringe was punctured into 
the rabbits’ heart and the 3 ml blood was drawn out (Figure 2.5). The blood was then 
transferred into 3ml blood collection tube and was kept in -20°C refrigerator. The 
whole blood count was performed using automated blood counter (Cell-Dyn ® 3700, 
Abbott Diagnostic, US). Following the blood collection, the rabbits were euthanized 
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with overdosed pentobarbital (1 ml/kg) (Dolethal, Lure Cedex, France) and subjected 
for post mortem.  
 
Figure 2.5 The syringe was directly injected into the heart and the blood was 
drawn out and collected into EDTA tube. The tubes containing blood were kept at 
4°C until usage.  
 
2.2.5 Collection of bronchioalveolar lavage (BAL) fluid 
The rabbits were first euthanized to cut open the chest to expose the trachea. The 
proximal area of the lung was cut out and BAL fluid from each rabbit was collected 
by lavaging the lung via trachea with 3 ml of PBS, twice (Figure 2.6). The collected 
BAL fluid was then centrifuge at 400x g for 5 min (4 °C). The supernatant was 
transferred into new 1.5 ml collection tube and stored at -70°C.  The pellets were 
then re-suspended in PBS and proceed with standard cell counting to be used in the 
cytospin method and whole white blood cell count.  
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Figure 2.6 Cross section of the rabbit during BAL fluid collection. The trachea 
was cut at epiglottis area (A). The syringe containing 3 mL of 1X PBS was inserted 
through the opening area. The BAL fluid was then collected in 1.5 mL tube. 
 
2.2.6 Preparation for cytospun of BAL fluid 
For this purpose, the numbers of cells were adjusted to 1x105 cells/ml. About 100 µl 
of BAL fluid cell suspension was transferred into cytofunnel attached with cytoslide. 
The cytofunnel containing cells was then placed into cytospin machine (Thermo 
Scientific Shandon Cytospin® 4 Cytocentrifuge, US). The cytospin was closed and 
the samples were spun at 1500 rpm to avoid cell death for 5 mins. After the cytospin 
was stopped, the filter was carefully removed from cytofunnel, without contacting 
the cell smears on the slides. The slides were left air dried in a flat layer on the slide 
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prior to standard Wreight-Giemsa staining process. Identification process of the 
inflammatory cell and cell scoring was done by a pathologist.  
2.2.7 Whole blood count for inflammatory cell 
The inflammatory cell count was done in order to observe the pattern of the 
inflammatory cell infiltration into the airway structure following the Ova-induced 
injury. The pellet from BAL fluid was diluted into 1x PBS with ratio 1:10. For 
counting purpose, 100 µl of BAL fluid was injected into an automated blood counter 
(Cell Dyn 3700 SL, Abbott Labortories, US). The inflammatory cell counting was 
expressed as inflammatory cell percentage (%). 
2.2.8 Collection, processing and sectioning the lung tissue 
The lung and trachea of the rabbits were collected right after BAL fluid collected. 
The lung was divided into two parts, where right lung was fixed in 10% (v/v) 
formalin for histological study meanwhile left lung was kept for future study. 
Twenty-four hours after fixation in 10% formalin, the right lung was cut in cross 
section manner, into small blocks and placed in histological cassette (Figure 2.7). 
The histological cassettes containing tissues were then transferred into an automated 
Excelsior ES Tissue Processor (Thermo Fisher Scientific, US) and left overnight. In 
this stage, the tissues were subjected to dehydration, clearing and infiltration process. 
Once the tissues were processed, the tissue blocks were removed from the machine 
and transferred into the tissue embedding machine (Shandon Histocentre 3 
Embedding Centre, US), where the tissue blocks were placed into embedding 
cassettes and filled with paraffin. The paraffin-filled embedding cassettes were left 
on cold platform until hardened and subjected to sectioning into 5 micron thickness 
using a microtome (Accu-Cut® SRM™ 200, Sakura®, US). The tissue ribbons were 
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left air-dried on normal slides (haematoxylin & eosin (H&E) staining, alcian blue-
periodic Acid-Schiff (AB-PAS) staining) and polysine-coated slides 
(immunohistochemical (IHC) staining) process.  
Lobes 1
Lobes 2
Lobes 3
Lobes 4
Bronchi
 
Figure 2.7 Diagram of the lung of the rabbit. All lobes (lobes 1, 2, 3 and 4) were 
cut in cross section manner (double-arrowhead), so that the internal airway structure 
of the lung can be observed and examined under microscope for further analysis. 
 
2.2.9 Heamatoxylin & Eosin (H&E) staining  
Lung sections were subjected to the H&E staining using standard protocol. The lung 
sections were deparaffinised in xylene twice for 2 min and dehydrated in gradient 
series of ethanol (100%, 90%, 80%, 70% and 50%) for 2 min. The slides were then 
rinsed under running tap water for 2 min. After that, the slides were immersed in 
Harris-haematoxylin solution (Accustain®, Sigma Aldrich, Germany) for 11 min and 
rinsed with running tap water until blue colour dye of Harris-haematoxylin 
